New research indicates that patients who stop using new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end traditional diet and exercise programs.
Research printed in a major health publication points out that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month once they quit.
"People using these medications must be cognizant of the potential of quick rebound weight gain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment weight in about a year and a half.
Comparing Therapies
The study, which reviewed 37 of trials involving over 9,000 of patients, contrasted the results of GLP-1 agonists with other pills.
Scientists point out that people who lose weight through diet and exercise typically see a slower weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Nutrition scientists suggest the mode of action of the drugs is key to understanding the heightened rebound.
These medications mimic a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the system to produce less of its own natural GLP-1, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, due to the significant potential of weight regain, the treatment might need to be long-term.
This view is echoed by drug manufacturers, who say that the findings "emphasize the chronic nature of obesity," comparing it to managing conditions like diabetes.
User Accounts
Users who have discontinued the jabs describe a powerful return of cravings.
"It felt as if a trigger activating and you become ravenous," said a patient.
This difficulty is compounded if patients have not established sustainable lifestyle or habit changes during therapy.
Significant Adoption
Recent estimates show that a significant number of adults in the UK have tried these injections in the past year, with interest being substantial.
- Use is greater among females than men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are effective tools for weight loss, they are not a standalone solution and lasting health benefits hinges on integrated lifestyle support.
